Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297966720> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4297966720 endingPage "504" @default.
- W4297966720 startingPage "1498" @default.
- W4297966720 abstract "Previous trials of interferon beta in multiple sclerosis (MS) have shown efficacy, but the degree of clinical benefit remains uncertain, and the optimum dose is not known. We undertook a double-blind, placebo-controlled study in relapsing/remitting MS to investigate the effects of subcutaneous interferon beta-1a.560 patients with Kurtzke expanded disability status scale (EDSS) scores of 0-5.0, from 22 centres in nine countries, were randomly assigned subcutaneous recombinant interferon beta-1a 22 microg (n=189), or 44 microg (n=184), or placebo (n=187) three times a week for 2 years. Neurological examinations were done every 3 months. All patients had MRI twice yearly and 205 had monthly scans in the first 9 months of treatment. Analysis was by intention to treat.Clinical data on 533 (95%) patients were available at 2 years. The relapse rate was significantly lower at 1 and 2 years with both doses of interferon beta-1a than with placebo (mean number per patient 1.82 for 22 microg group, 1.73 for 44 microg group vs 2.56 for placebo group: risk reductions 27% [95% CI 14-39] and 33 [21-44]). Time to first relapse was prolonged by 3 and 5 months in the 22 microg and 44 microg groups respectively, and the proportion of relapse-free patients was significantly increased (p<0.05). Interferon beta-1a delayed progression in disability, and decreased accumulated disability during the study. The accumulation of burden of disease and number of active lesions on MRI was lower in both treatment groups than in the placebo group.Subcutaneous interferon beta-1a is an effective treatment for relapsing/remitting MS in terms of relapse rate, defined disability, and all MRI outcome measures in a dose-related manner, and it is well tolerated. Longer-term benefits may become clearer with further follow-up and investigation." @default.
- W4297966720 created "2022-10-01" @default.
- W4297966720 date "1998-11-07" @default.
- W4297966720 modified "2023-09-29" @default.
- W4297966720 title "Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group." @default.
- W4297966720 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9820297" @default.
- W4297966720 hasPublicationYear "1998" @default.
- W4297966720 type Work @default.
- W4297966720 citedByCount "244" @default.
- W4297966720 countsByYear W42979667202012 @default.
- W4297966720 countsByYear W42979667202013 @default.
- W4297966720 countsByYear W42979667202014 @default.
- W4297966720 countsByYear W42979667202015 @default.
- W4297966720 countsByYear W42979667202016 @default.
- W4297966720 countsByYear W42979667202017 @default.
- W4297966720 countsByYear W42979667202018 @default.
- W4297966720 countsByYear W42979667202019 @default.
- W4297966720 countsByYear W42979667202020 @default.
- W4297966720 countsByYear W42979667202021 @default.
- W4297966720 countsByYear W42979667202022 @default.
- W4297966720 countsByYear W42979667202023 @default.
- W4297966720 crossrefType "journal-article" @default.
- W4297966720 hasConcept C126322002 @default.
- W4297966720 hasConcept C142724271 @default.
- W4297966720 hasConcept C203014093 @default.
- W4297966720 hasConcept C204787440 @default.
- W4297966720 hasConcept C27081682 @default.
- W4297966720 hasConcept C2780640218 @default.
- W4297966720 hasConcept C2780892749 @default.
- W4297966720 hasConcept C2908698914 @default.
- W4297966720 hasConcept C2910198813 @default.
- W4297966720 hasConcept C2994247566 @default.
- W4297966720 hasConcept C535046627 @default.
- W4297966720 hasConcept C71924100 @default.
- W4297966720 hasConcept C90924648 @default.
- W4297966720 hasConceptScore W4297966720C126322002 @default.
- W4297966720 hasConceptScore W4297966720C142724271 @default.
- W4297966720 hasConceptScore W4297966720C203014093 @default.
- W4297966720 hasConceptScore W4297966720C204787440 @default.
- W4297966720 hasConceptScore W4297966720C27081682 @default.
- W4297966720 hasConceptScore W4297966720C2780640218 @default.
- W4297966720 hasConceptScore W4297966720C2780892749 @default.
- W4297966720 hasConceptScore W4297966720C2908698914 @default.
- W4297966720 hasConceptScore W4297966720C2910198813 @default.
- W4297966720 hasConceptScore W4297966720C2994247566 @default.
- W4297966720 hasConceptScore W4297966720C535046627 @default.
- W4297966720 hasConceptScore W4297966720C71924100 @default.
- W4297966720 hasConceptScore W4297966720C90924648 @default.
- W4297966720 hasIssue "9139" @default.
- W4297966720 hasLocation W42979667201 @default.
- W4297966720 hasOpenAccess W4297966720 @default.
- W4297966720 hasPrimaryLocation W42979667201 @default.
- W4297966720 hasRelatedWork W1986008120 @default.
- W4297966720 hasRelatedWork W2005527422 @default.
- W4297966720 hasRelatedWork W2036769788 @default.
- W4297966720 hasRelatedWork W2159343111 @default.
- W4297966720 hasRelatedWork W2408776304 @default.
- W4297966720 hasRelatedWork W2411164510 @default.
- W4297966720 hasRelatedWork W2466062308 @default.
- W4297966720 hasRelatedWork W2552209029 @default.
- W4297966720 hasRelatedWork W26528964 @default.
- W4297966720 hasRelatedWork W3028806530 @default.
- W4297966720 hasVolume "352" @default.
- W4297966720 isParatext "false" @default.
- W4297966720 isRetracted "false" @default.
- W4297966720 workType "article" @default.